Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

OBJECTIVE: In the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated cabozantinib in patients who had received sor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L, Lim, Ho Yeong, Baron, Ari D, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C, Milwee, Steven, El-Khoueiry, Anthony B, Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7451459/
https://ncbi.nlm.nih.gov/pubmed/32847838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000714
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars